The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development
Open accessAbstract
Nanomaterials, with their size range (1-100 nm) that corresponds to basic biological materials such as DNA, vastly increased surface area (1000 m 2 /g) and unique mechanical, electronic, photonic and magnetic properties are projected to have a wide range of applications from drug and gene delivery to biomedical imaging and more recently to personalized medicine.The major advantages of using nanomaterials as a carrier for anticancer agents are the possibility of targeted delivery to the tumor, tumor imaging, their ability to hold thousands of molecules of a drug and also their ability to overcome solubility, stability and resistance issues.Currently, there are several nanotechnology-enabled diagnostic and therapeutic agents undergoing clinical trials and a few are already approved by the FDA.Targeted delivery of anticancer agents is achieved by exploiting a unique characteristic of the tumor cells called "the Enhanced Permeation and Retention Effect (EPR effect).In addition to this passive targeting based mainly on size, the nanoparticle surface may be modified with a variety of ligands that would interact with specific receptors over-expressed on the surface of the tumor cells, thus imparting specificity for active targeting.Site-specific release of a drug contained in a nanoparticulate system by the application of external stimuli such as hyperthermia to a thermosensitive device is another innovative strategy for targeted delivery.This review provides an update on the FDA approved cancer nanomedicines such as Abraxane, Doxil, daunoxome, Oncaspar, DepoCyt and those in nanoplatforms that have reached an advanced stage of clinical development utilizing liposomes, lipid nanoparticles, lipoplexes, albumin nanospheres, thermosensitive devices, micelles and gold nanoparticles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
LIPOSOMAL DAUNORUBICIN OVERCOMES DRUG RESISTANCE IN HUMAN BREAST, OVARIAN AND LUNG CARCINOMA CELLS
Sadava, D., Coleman, A., & Kane, S. E. (2002) · Journal of Liposome Research · doi:10.1081/lpr-120016196 · Cited by 63
Liposome‐associated retinoic acid: Increased in vitro antiproliferative effects on neoplastic cells
Nastruzzi, C., Walde, P., Menegatti, E., & Gambari, R. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)80030-m · Cited by 30
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review
Hossen, S., Hossain, M. K., Basher, M. K., Mia, M. N. H., Rahman, M. T., & Uddin, M. J. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2018.06.005 · Cited by 998
Arias, L. S., Pessan, J. P., Vieira, A. P. M., Lima, T. M. T. D., Delbem, A. C. B., & Monteiro, D. R. (2018) · Antibiotics · doi:10.3390/antibiotics7020046 · Cited by 714
Surface Functionalization and Targeting Strategies of Liposomes in Solid Tumor Therapy: A Review
Riaz, M., Riaz, M., Zhang, X., Lin, C., Wong, K., Chen, X., Zhang, G., Lu, A., & Yang, Z. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010195 · Cited by 509
Metadata
- Authors
- Pillai, G.
- Venue
- SOJ Pharmacy & Pharmaceutical Sciences
- Publisher
- Symbiosis Group
- Published
- 2014
- ISSN
- 2374-6866 (ISSN-L)
- OpenAlex
- W2168127523
- Cited by
- 187
- References
- 6
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development. https://app.cochat.ai/papers/10.15226/2374-6866/1/2/00109
- The paper
- Pillai, G. (2014). Nanomedicines for Cancer Therapy: An Update of FDA Approved and Those under Various Stages of Development. SOJ Pharmacy & Pharmaceutical Sciences. https://doi.org/10.15226/2374-6866/1/2/00109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.